AgingResearch.NewsJoin free

Phase 3Status unknown

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

A Phase III Trial in Healthy Indonesian Women Ages 18-45 to Evaluate the Immunogenicity and Safety of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

Sponsor
Beijing Health Guard Biotechnology, Inc (Industry)
Enrolment
1,260 enrolled
Conditions
Human Papillomavirus Infection
Interventions
Nonavalent HPV study vaccine; GARDASIL® 9
Ages
adults
Registry
NCT06207175

Full record on ClinicalTrials.gov

From the registry

This Study to Evaluate the Immunogenicity and Safety of Candidate Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) Administered Intramuscularly in Healthy Female Participants Aged 18 to 45 Years

Primary outcomes

  • Geometric mean titer (GMT) for anti-HPV neutralizing antibodies 30 days after full vaccination
  • Seroconversion Rate (SCR) for anti-HPV neutralizing antibodies 30 days after full vaccination

History

  1. Study completion

  2. Primary completion

  3. Last registry update

  4. Registered

  5. Started